Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $800.84M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
RIGL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Rigel Pharmaceuticals, Inc.NASDAQ: RIGL
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $30.65M rose 10.6% year over year, ahead of the +5.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.
Context
- Selling, general & admin amounted to 39.4% of revenue in FY2025, down 23.7 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $215.72M (+86.1%) for the fiscal year ending Dec 2026, a step up from the +2.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $30.65M+2.2% QoQ
- Last fiscal yearDec 2025
- $115.9M+2.5% YoY
- LTMMar 2026
- $118.84M+5.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 115.9M USD
- Year-over-year change
- +2.5%
- 4-year CAGR
- +6.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 115.9M | +2.5% |
| FY2024 | 2024-12-31 | 113.06M | +6.9% |
| FY2023 | 2023-12-31 | 105.74M | -6.0% |
| FY2022 | 2022-12-31 | 112.45M | +22.4% |
| FY2021 | 2021-12-31 | 91.89M | — |
Selling, General & Admin vs competitors
How RIGL compares with its peers on the latest reported figures
- RIGL's LTM Mar 2026 selling, general & admin of $118.84M is the 2nd highest of the 10 companies compared; the peer median is $34.4M.
- Its year-over-year change of +5.8% is the 4th highest of 9, against a peer median of -1.1%.
- Selling, general & admin amounts to 39.6% of revenue for RIGL, versus a peer median of 178.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $533.92M | +3.0% | +4.1% | 21.9% | |
| LTM Mar 2026 | $118.84M | +5.8% | +1.0% | 39.6% | |
| LTM Mar 2026 | $88.42M | +83.1% | +48.1% | 178.3% | |
| LTM Aug 2026 | $78.21M | +57.0% | +11.6% | 11.1% | |
| LTM Mar 2026 | $52.28M | -5.2% | +10.5% | — | |
| LTM Mar 2026 | $34.4M | -16.4% | -5.4% | 98.7% | |
| LTM Mar 2026 | $21.28M | -23.4% | -6.3% | — | |
| LTM Mar 2026 | $19.76M | -28.1% | -0.2% | 3951.0% | |
| LTM Jun 2024 | $14.78M | — | -14.4% | 227.7% | |
| LTM Mar 2026 | $13.02M | +27.1% | +2.6% | 2479.6% | |
| Peer median (excluding RIGL) | $34.4M | -1.1% | +2.6% | 178.3% | |
Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M |
| Cost of Revenue | 1.08M | 1.75M | 7.11M | 18.65M | 19.62M |
| Gross Profit | 148.15M | 118.49M | 109.77M | 160.63M | 274.66M |
| Gross Margin | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Research & Development | 65.24M | 60.27M | 24.52M | 23.38M | 33.3M |
| Selling, General & Admin | 91.89M | 112.45M | 105.74M | 113.06M | 115.9M |
| Operating Expenses | 160.65M | 174.04M | 130.26M | 136.44M | 149.2M |
| Depreciation & Amortization | 1.16M | 998K | 1.24M | 2.23M | 2.42M |
| EBITDA | (11.29M) | (53.87M) | (16.98M) | 28.51M | 131.56M |
| EBITDA Margin | -7.6% | -44.8% | -14.5% | 15.9% | 44.7% |
| Operating Income | (12.5M) | (55.55M) | (20.49M) | 24.19M | 125.47M |
| Operating Margin | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Interest Income | 47K | 684K | 2.27M | 2.09M | 3.68M |
| Interest Expense | 4.86M | 3.71M | 6.87M | 7.92M | 7.32M |
| Other Income / Expenses | (4.81M) | (3.02M) | (4.6M) | (5.83M) | (3.64M) |
| Income Before Tax | (17.31M) | (58.57M) | (25.09M) | 18.37M | 121.83M |
| Pre-Tax Margin | -11.6% | -48.7% | -21.5% | 10.2% | 41.4% |
| Income Tax Expense | 605K | 0 | 0 | 881K | (245.2M) |
| Net Income | (17.91M) | (58.57M) | (25.09M) | 17.49M | 367.02M |
| Net Margin | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| EPS (Basic) | (1.10) | (3.40) | (1.44) | 0.99 | 20.40 |
| EPS (Diluted) | (1.10) | (3.40) | (1.44) | 0.99 | 19.48 |
| Weighted Avg Shares | 17.05M | 17.24M | 17.4M | 17.58M | 17.99M |
| Weighted Avg Shares (Diluted) | 17.05M | 17.24M | 17.4M | 17.69M | 18.84M |
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.